Show simple item record

dc.contributor.authorBousquet, Jean
dc.contributor.authorDuchateau, J.
dc.contributor.authorPignat, J. C.
dc.contributor.authorFayol, C.
dc.contributor.authorMarquis, P.
dc.contributor.authorMariz, S.
dc.contributor.authorWare, John E. Jr.
dc.contributor.authorValentin, B.
dc.contributor.authorBurtin, B.
dc.date2022-08-11T08:10:40.000
dc.date.accessioned2022-08-23T17:16:24Z
dc.date.available2022-08-23T17:16:24Z
dc.date.issued1996-08-01
dc.date.submitted2010-06-18
dc.identifier.citationJ Allergy Clin Immunol. 1996 Aug;98(2):309-16. <a href="http://dx.doi.org/10.1016/S0091-6749(96)70155-0">Link to article on publisher's site</a>
dc.identifier.issn0091-6749 (Linking)
dc.identifier.doi10.1016/S0091-6749(96)70155-0
dc.identifier.pmid8757208
dc.identifier.urihttp://hdl.handle.net/20.500.14038/47391
dc.description.abstractBACKGROUND AND AIM: Perennial allergic rhinitis impairs social life, but it is not known whether quality of life may be improved when patients are treated with an H1-blocker. A randomized, double-blind, placebo-controlled study was carried out with cetirizine to assess the effect of this drug on quality of life. METHODS: Two hundred seventy-four patients with perennial allergic rhinitis were tested. Quality of life was measured by using the Medical Outcome Study Short-Form Health Survey (SF-36) questionnaire. After a 2-week run-in period, cetirizine, 10 mg once daily, (136 patients) or placebo (138 patients) was given for the next 6 weeks. The SF-36 questionnaire was administered after the run-in period (at the start of treatment) and after 1 and 6 weeks of treatment. Symptom-medication scores were measured daily during the study. RESULTS: After the run-in period (baseline), there were no significant differences between the cetirizine and placebo groups in terms of symptoms or quality-of-life scores. After 6 weeks of treatment, percentage of days without rhinitis or with only mild rhinitis symptoms was significantly greater in the cetirizine group in comparison with the placebo group (p < 0.0001, Mann-Whitney U test). All of the nine quality-of-life dimensions were significantly improved (from p = 0.01 to p < 0.0001, Mann-Whitney U test) after 1 and 6 weeks of cetirizine treatment compared with placebo. There was no improvement in the placebo group. CONCLUSIONS: This study is the first to demonstrate that an H1-blocker, cetirizine, can improve quality of life for patients with perennial allergic rhinitis.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=8757208&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/S0091-6749(96)70155-0
dc.subjectAdolescent
dc.subjectAdult
dc.subjectBelgium
dc.subjectCetirizine
dc.subjectDouble-Blind Method
dc.subjectFollow-Up Studies
dc.subjectFrance
dc.subject*Health Surveys
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectPatient Compliance
dc.subject*Quality of Life
dc.subject*Questionnaires
dc.subjectRhinitis, Allergic, Perennial
dc.subjectTreatment Outcome
dc.subjectBiostatistics
dc.subjectEpidemiology
dc.subjectHealth Services Research
dc.titleImprovement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire
dc.typeJournal Article
dc.source.journaltitleThe Journal of allergy and clinical immunology
dc.source.volume98
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/qhs_pp/531
dc.identifier.contextkey1363365
html.description.abstract<p>BACKGROUND AND AIM: Perennial allergic rhinitis impairs social life, but it is not known whether quality of life may be improved when patients are treated with an H1-blocker. A randomized, double-blind, placebo-controlled study was carried out with cetirizine to assess the effect of this drug on quality of life.</p> <p>METHODS: Two hundred seventy-four patients with perennial allergic rhinitis were tested. Quality of life was measured by using the Medical Outcome Study Short-Form Health Survey (SF-36) questionnaire. After a 2-week run-in period, cetirizine, 10 mg once daily, (136 patients) or placebo (138 patients) was given for the next 6 weeks. The SF-36 questionnaire was administered after the run-in period (at the start of treatment) and after 1 and 6 weeks of treatment. Symptom-medication scores were measured daily during the study.</p> <p>RESULTS: After the run-in period (baseline), there were no significant differences between the cetirizine and placebo groups in terms of symptoms or quality-of-life scores. After 6 weeks of treatment, percentage of days without rhinitis or with only mild rhinitis symptoms was significantly greater in the cetirizine group in comparison with the placebo group (p < 0.0001, Mann-Whitney U test). All of the nine quality-of-life dimensions were significantly improved (from p = 0.01 to p < 0.0001, Mann-Whitney U test) after 1 and 6 weeks of cetirizine treatment compared with placebo. There was no improvement in the placebo group.</p> <p>CONCLUSIONS: This study is the first to demonstrate that an H1-blocker, cetirizine, can improve quality of life for patients with perennial allergic rhinitis.</p>
dc.identifier.submissionpathqhs_pp/531
dc.contributor.departmentDepartment of Quantitative Health Sciences
dc.source.pages309-16


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record